Innovation Pharmaceuticals Inc (IPIX)

[PlentyParanoid]

I Agree. It looks like, at minimum, Soligenix style phase 3: cisplatin 100 mg every 3 weeks and cancer location limited to oral cavity and oropharynx. Unless there was something in brilacidin p2 trial data we are not aware of.

Only thing I can think of is that IPIX did heavy exclusion of subjects with SOM in cisplatin Q3W group and FDA thinks they do belong. That would have to be really, really heavy exclusion.